RECRUITING Phase 4 ClinicalTrials.gov

Supplementation Absorption Comparison

Sponsor: RDC Clinical Pty Ltd • ClinicalTrials.gov ID: NCT07791797

Registry updated: 2026-09-10

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The goal of this interventional study is to compare the absorption of supplements with and without absorption enhancing technology in healthy volunteers. We will be testing vitamin D3 and omega 3 in both males and females 18 years and older. Part A will comprise of two arms receiving a single dose of omega-3 supplement, and two arms who will receive vitamin D3 supplement daily for 7 days. Part B comprises of two arms who will receive vitamin D3 supplement daily for 6 weeks.

Interventions

Aquacelle® Omega 3 (Dietary supplement)
Participants will consume 1 capsule containing 315mg EPA and DHA
Comparator Omega 3 (Dietary supplement)
Participants will consume 1 capsule containing 315mg EPA and DHA
Plexosome® Vitamin D3 (Dietary supplement)
Participants will have 1000IU vitamin D3 each day for 7 days
Comparator Vitamin D3 (Dietary supplement)
Participants will have 1000IU vitamin D3 each day for 7 days
Plexosome® Vitamin D3 6 weeks (Dietary supplement)
Participants will have 1000IU vitamin D3 each day for 6 weeks
Comparator Vitamin D3 6 weeks (Combination product)
Participants will have 1000IU vitamin D3 each day for 6 weeks

Eligibility criteria

Part A: Inclusion Criteria: * Adults 18 years and older * Generally healthy * BMI 18.5-29.9 kg/m2 * Able to provide informed consent * Agree to not participate in another clinical trial while enrolled in this trial * Agree not to change current diet and/or exercise frequency or intensity during entire study period * Participant's ability to participate fully and comply with demands of the study including attendance at all scheduled blood collection time points Exclusion Criteria: * Have a serious illness e.g. mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, kidney disease, liver disease or heart conditions * Have an unstable illness e.g. diabetes and thyroid gland dysfunction * Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years * Significant change in diet in the past 1-month (e.g., removal of a food group or calorie restriction) * Active smokers, nicotine use or drug (prescription or illegal substances) abuse * Chronic past and/or current alcohol use (\>21 alcoholic drinks week) * Pregnant or lactating women * Allergic to any of the ingredients in enhanced or standard formula * Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month (excluding RDC Clinical trials) * Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion * Regular use within the past 4 weeks of supplements containing the trial product Part B: The above criteria apply, plus baseline serum 25(OH)D \<20.0 ng/mL (\<50.0 nm/L)

Conditions

Healthy Volunteer

Locations

RDC Clinical — Fortitude Valley, Queensland, Australia

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment